K 103 IP

Drug Profile

K 103 IP

Alternative Names: K-103-IP; K-103-PA

Latest Information Update: 21 Jun 2016

Price : $50

At a glance

  • Originator Kowa Pharmaceutical
  • Class Analgesics; Anti-inflammatories
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute pain; Inflammation

Most Recent Events

  • 21 Jun 2016 No recent reports on development identified - Phase-III for Acute pain in China (Topical)
  • 20 Jun 2016 Phase-III development for Acute pain and Inflammation is ongoing in USA
  • 01 Dec 2014 Kowa terminates phase III trial in Acute pain in USA (Topical) (NCT02089425)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top